VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma

OBJECTIVES: To compare flow cytometric minimal residual disease (MRD) data obtained using the EuroFlow approach, including the CD38-multiepitope (ME) antibody or the VS38c antibody. METHODS: We evaluated 29 bone marrow samples from patients with multiple myeloma (MM), of whom 15 had received daratum...

Descripción completa

Detalles Bibliográficos
Autores principales: Broijl, Annemiek, de Jong, Augustinus C M, van Duin, Mark, Sonneveld, Pieter, Kühnau, Jesper, van der Velden, Vincent H J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973271/
https://www.ncbi.nlm.nih.gov/pubmed/34643211
http://dx.doi.org/10.1093/ajcp/aqab163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8973271/
https://www.ncbi.nlm.nih.gov/pubmed/34643211
http://dx.doi.org/10.1093/ajcp/aqab163

Ejemplares similares